Genocea Biosciences Inc. (NASDAQ:GNCA) shares were down 3.8% during trading on Thursday . The company traded as low as $4.22 and last traded at $4.30, with a volume of 195,023 shares changing hands. The stock had previously closed at $4.47.

A number of analysts recently weighed in on GNCA shares. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Tuesday, July 5th. FBR & Co restated a “buy” rating and issued a $17.00 price objective on shares of Genocea Biosciences in a report on Friday, April 1st. Stifel Nicolaus increased their price objective on Genocea Biosciences from $11.00 to $13.00 and gave the company a “buy” rating in a report on Friday, April 1st. Finally, Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a report on Friday, April 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $18.13.

The firm has a 50 day moving average price of $4.24 and a 200 day moving average price of $4.32. The firm’s market capitalization is $121.34 million.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, May 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. Analysts predict that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current year.

An institutional investor recently raised its position in Genocea Biosciences stock. AWM Investment Company Inc. increased its stake in Genocea Biosciences Inc. (NASDAQ:GNCA) by 45.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 715,000 shares of the company’s stock after buying an additional 222,900 shares during the period. AWM Investment Company Inc. owned 2.54% of Genocea Biosciences worth $3,768,000 at the end of the most recent reporting period.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.